Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | TNF | P01375 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26619213 | 0.81 | ALDH1A1 (0.41) | ALDH1A1NPSR1TSHRCES1L3MBTL1 | |
| SCHEMBL19224643 | 0.76 | ALDH1A1 (0.50) | ALDH1A1CES1L3MBTL1MAPTKMT2A | |
| SCHEMBL19224644 | 0.75 | ALDH1A1 (0.45) | ALDH1A1NPSR1TSHRMAPTKMT2A | |
| SCHEMBL18039456 | 0.69 | NPSR1 (0.47) | ALDH1A1NPSR1TSHRL3MBTL1MAPT | |
| SCHEMBL7367074 | 0.68 | CES1 (0.41) | ALDH1A1NPSR1TSHRCES1MAPT | |
| SCHEMBL19948875 | 0.66 | ALDH1A1 (0.40) | ALDH1A1NPSR1TSHRMAPK1CES1 | |
| SCHEMBL12894510 | 0.65 | ALDH1A1 (0.45) | ALDH1A1NPSR1TSHRL3MBTL1MAPT | |
| SCHEMBL19948901 | 0.64 | ALDH1A1 (0.38) | ALDH1A1NPSR1CES1MAPTKMT2A | |
| SCHEMBL2251389 | 0.64 | ALDH1A1 (0.58) | ALDH1A1TSHRMAPK1L3MBTL1MAPT | |
| SCHEMBL13819563 | 0.63 | ALDH1A1 (0.47) | ALDH1A1NPSR1TSHRL3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118994190-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-118994191-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2024-11-22 | — | — | CN | disclosed |
| CN-114437105-B | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2024-10-11 | — | — | CN | disclosed |
| CN-114437105-A | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2022-05-06 | — | — | CN | disclosed |
| CN-109071504-B | Inhibitors of receptor interacting protein kinase 1 | 戴纳立制药公司 | 2022-03-08 | — | — | CN | disclosed |
| US-20180099981-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2018-04-12 | — | — | US | disclosed |
| US-9896458-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2018-02-20 | — | — | US | disclosed |
| US-20180022759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2018-01-25 | — | — | US | disclosed |
| US-9815850-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815850-B2 | Compounds, compositions and methods | DENALI THERAPEUTICS INC. (US) | 2017-11-14 | — | — | US | disclosed |
| WO-2017136727-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. (US) | 2017-08-10 | — | — | WO | disclosed |
| US-20170226127-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2017-08-10 | — | — | US | disclosed |
| US-20170226127-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2017-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099981-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | PIK3CA, PLK1, PIK3CB | ALDH1A1 4405/4885NPSR1 4297/4885TSHR 4584/4885 |
| US-20180022759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | PIK3CA, PLK1, PIK3CB | ALDH1A1 4405/4885NPSR1 4297/4885TSHR 4584/4885 |
| US-20170226127-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | PIK3CA, PLK1, PIK3CB | ALDH1A1 4405/4885NPSR1 4297/4885TSHR 4584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.